Dyne Therapeutics Insider Buy Signals Strategic Confidence in Muscle‑Targeted Pipeline
Dyne Therapeutics insider buy: CMO Kerr Douglas buys 8,000 shares and 12,000 RSUs, signaling long‑term optimism amid market volatility.
3 minutes to read
DYNE THERAPEUTICS INC
Insider Buy Signals Bullish Outlook for Dyne Therapeutics
Posner’s latest 2,500‑share buy at $16 fuels optimism for Dyne Therapeutics, hinting at a bullish outlook amid its muscle‑therapy breakthroughs.
3 minutes to read